European Patent to Strengthen Medigene's Dendritic Cell (DC) Vaccines Program
(Thomson Reuters ONE) -
Medigene AG /
European Patent to Strengthen Medigene's Dendritic Cell (DC) Vaccines Program
. Processed and transmitted by NASDAQ OMX Corporate Solutions.
The issuer is solely responsible for the content of this announcement.
Press Release
Martinsried/Munich, 5 March 2015. Biotechnology company, Medigene AG (MDG1,
Frankfurt, Prime Standard) announces that the European Patent Office has granted
European Patent No. 2004807 "Composition for the preparation of mature dendritic
cells", relating to the manufacturing of mature dendritic cells co-developed by
scientists of today's Medigene Immunotherapies. The patent will have a term
until 2027 and is licensed exclusively to Medigene Immunotherapies (formerly
Trianta Immunotherapies) by the Helmholtz Zentrum München.
Prof. Dolores Schendel, CSO of Medigene AG, comments: "This new patent will
substantially extend the protection for our innovative products. The patent
protects our unique process to generate polarised dendritic cells, the cocktail
used in the process and the derived polarised dendritic cells, which are being
used in the ongoing academic clinical trials and will be used in our upcoming
company-sponsored clinical study."
About Medigene's DC vaccines: The platform for the development of antigen-
tailored DC vaccines is the most advanced platform of the three highly
innovative and complementary immunotherapy platforms of Medigene Immunotherapies
(formerly Trianta Immunotherapies). Currently the DC vaccines are being
evaluated in two ongoing investigator-initiated trials in clinical phases II
(prostate cancer) and I/II (AML, acute myeloid leukaemia). Medigene concentrates
on the further development of DC vaccines in hematological malignancies and
plans to initiate a further clinical study in AML shortly.
Medigene's dendritic cell product platform allows the design of new generation
dendritic cell vaccines. Dendritic cells can take up antigens efficiently,
process them and present them on their surface in a form that can induce
antigen-specific T cells to proliferate and mature. This way T cells can
recognize and eliminate antigen-bearing tumour cells. Dendritic cells can also
induce natural killer cells (NK cells) to become active and attack tumour cells.
Scientists of Medigene Immunotherapies have developed new, fast and efficient
methods for preparing autologous (patient-specific) mature dendritic cells which
have relevant characteristics to activate both T cells and NK cells. The
dendritic cells can be loaded with various tumour antigens to treat different
types of cancer and are suited for treatment of minimal residual disease or use
in combination therapies.
Medigene AG is a publicly listed (Frankfurt: MDG1, prime standard) biotechnology
company headquartered in Martinsried near Munich, Germany. Medigene concentrates
on the development of personalized T cell immunotherapies with a focus on
hematological malignancies. Medigene is the first German biotech company to have
revenues from a marketed product, which is distributed by commercial partner
companies. Medigene has advanced drug candidates which are licensed to partners
and additional candidates in clinical development. The company is developing
highly innovative treatment platforms concentrating on cancer and autoimmune
diseases. For more information, please visit www.medigene.com.
This press release contains forward-looking statements representing the opinion
of Medigene as of the date of this release. The actual results achieved by
Medigene may differ significantly from the forward-looking statements made
herein. Medigene is not bound to update any of these forward-looking statements.
Medigene(®) is a registered trademark of Medigene AG. Medigene
Immunotherapies(TM) is a registered trademark of Medigene Immunotherapies GmbH.
Trianta Immunotherapies(TM) is a registered trademark of Medigene
Immunotherapies GmbH. These trademarks may be owned or licensed in select
locations only.
Contact Medigene
Julia Hofmann, Anja Clausnitzer
Tel.: +49 - 89 - 20 00 33 - 33 01
Email: investor(at)medigene.com
To unsubscribe from the press release distribution list, please visit:
http://www.medigene.de/unsubscribe
Press release as PDF:
http://hugin.info/132073/R/1899489/674839.pdf
This announcement is distributed by GlobeNewswire on behalf of
GlobeNewswire clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Medigene AG via GlobeNewswire
[HUG#1899489]
Unternehmensinformation / Kurzprofil:
Datum: 05.03.2015 - 07:30 Uhr
Sprache: Deutsch
News-ID 376337
Anzahl Zeichen: 5446
contact information:
Town:
Martinsried / München
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 163 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"European Patent to Strengthen Medigene's Dendritic Cell (DC) Vaccines Program"
steht unter der journalistisch-redaktionellen Verantwortung von
Medigene AG (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
